Evaluating photodynamic therapy as an adjuvant treatment for neovascular AMD: A comprehensive meta-analysis

Apr 20, 2025 by in OPHTHALMOLOGY Comments Off on Evaluating photodynamic therapy as an adjuvant treatment for neovascular AMD: A comprehensive meta-analysis

Abstract Purpose This study aimed to assess the role of photodynamic therapy (PDT) as an adjunct to anti-vascular endothelial growth factor (Anti-VEGF) intravitreal injections in the treatment of neovascular age-related…

read more

Utilizing generative AI in ophthalmic medical paper writing: Applications, limitations, and practical tools

Apr 20, 2025 by in OPHTHALMOLOGY Comments Off on Utilizing generative AI in ophthalmic medical paper writing: Applications, limitations, and practical tools

Generative Artificial Intelligence (GenAI) is increasingly impacting medical research and academic writing, including ophthalmology. While GenAI’s influence is expanding, there remains a lack of comprehensive literature that thoroughly addresses its…

read more

Triterpenoid saponin–mediated recovery of visual deficits in age-related macular degeneration (AMD): Double-blind, placebo-controlled, randomised clinical trial

Apr 20, 2025 by in OPHTHALMOLOGY Comments Off on Triterpenoid saponin–mediated recovery of visual deficits in age-related macular degeneration (AMD): Double-blind, placebo-controlled, randomised clinical trial

Abstract Purpose Recovery rate of rod photoreceptor sensitivity (S2 gradient) following a bleach is reduced in age-related macular degeneration (AMD) due to diminished delivery of retinol across a grossly altered…

read more

Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation

Apr 20, 2025 by in OPHTHALMOLOGY Comments Off on Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation

Abstract Purpose To evaluate the efficacy, durability and safety of intravitreal faricimab versus aflibercept over 48 weeks in patients with neovascular age-related macular degeneration (nAMD) from the LUCERNE China subpopulation….

read more
Get Clinical Tree app for offline access